MAPK9 and hepatocellular carcinoma: SLP2 affects the ubiquitin-proteasome degradation pathway of JNK2, thereby maintaining the protein stability of JNK2 and increasing the activity of SREBP1, which impacts the progression of hepatocellular carcinoma and lipid synthesis.